Artiva Biotherapeutics said AlloNK plus rituximab showed clinically meaningful 6-month improvements in disease activity and symptoms in an early Sjogren disease study. Safety data from 73 patients suggested potential for outpatient use.
published
Artiva Biotherapeutics said AlloNK plus rituximab showed clinically meaningful 6-month improvements in disease activity and symptoms in an early Sjogren disease study. Safety data from 73 patients suggested potential for outpatient use.
Latest documented BWB result
$APP market result
Sold the $280 10/9 Calls on $APP for $7.80
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.